Pill Identifier App

Renovo Positive Data for Juvista

Renovo Group plc (LSE : RNVO) announced today positive results in a clinical trial designed to establish the safety and efficacy of a new formulation of the scar revision drug Juvista intended for use in children. The study of Juvista Paediatri included 84 patients and the statistical analysis (p<0.0001) indicated a profound result much more than the hurdle rate of 21% improvement set in the phase III trial.

Highlights of the announcement include: • 84 healthy male and female subjects participated in a double blind, placebo controlled, within subject comparative study of the safety and efficacy of Juvista and Juvista Paediatric on scar appearance after 12 months using the Global Scar Comparison Scale (the primary endpoint agreed with the EMA for Renovo’s ongoing EU Phase III trial). • Single doses of Juvista Paediatric administered immediately after wound closure (500 and 1000 ng/100μl/linear cm of wound margin) significantly improved the appearance of surgical 1cm incision scars compared to placebo (p<0.0001) when assessed by an expert panel using the Global Scar Comparison Scale at 12 months. • Statistically significant improvements were also observed for single doses of Juvista Paediatric (500 and 1000 ng/100μl/linear cm of wound margin) for the investigator’s assessment directly on the patient at 12 months using the Global Scar Comparison Scale (p<0.001, p<0.0001 respectively). • The current top dose of Juvista in the ongoing adult EU Phase III efficacy study (500 ng/100μl/linear cm of wound margin administered twice) was re-confirmed as the optimal dose for improvement of scar appearance (p<0.0001) as no further efficacy (in fact a slight decrease) was achieved after dosing 1000ng /100μl/linear cm of wound margin, either once or twice.

Please find the press release, as well as a ‘Buy’ note from Panmure Gordon and a Nomura Code note attached here.

For further information please contact Tim Anderson, Catherine Breen or Jessica Fontaine.

Kind regards, Jessica Fontaine Buchanan Communications A WPP Company Tel: +44 (0)20 7466 5000 Fax: +44 (0)20 7466 5001 Email: jessicaf@buchanan.uk.com Reg. in Eng. No. 1499986 45 Moorfields London EC2Y9AE Vat No. GB 245 7021 77

Documents Attached[3]

Nomura Code note Renovo<http://db.buchanan.uk.com/handlers/fileDownloadH.jsp?id=8617709546227479769&messageSendId=-6757878648778109388>

Renovo Juvista Phase I Announcement<http://db.buchanan.uk.com/handlers/fileDownloadH.jsp?id=-6170348013406451861&messageSendId=-6757878648778109388>

Panmure Gordon note Renovo 23.11.10<http://db.buchanan.uk.com/handlers/fileDownloadH.jsp?id=-7031538296838599360&messageSendId=-6757878648778109388>


For our Internet Broadcasting services please visit our main website<http://www.buchanan.uk.com>


Buchanan Communications Reg. in Eng. No. 1499986 45 Moorfields London EC2Y9AE Vat No. GB 245 7021 77


Posted: November 2010

View comments